|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.70 USD | +0.44% |
|
-3.06% | +42.53% |
| 06-29 | Celldex Therapeutics, Inc.(NasdaqCM:CLDX) added to Russell Small Cap Comp Growth Benchmark | CI |
| 06-29 | Celldex Therapeutics, Inc.(NasdaqCM:CLDX) added to Russell 2500 Growth Benchmark | CI |
Company Valuation: Celldex Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,803 | 2,099 | 2,169 | 1,677 | 1,805 | 3,024 | - | - |
| Change | - | 16.42% | 3.32% | -22.7% | 7.65% | 67.57% | - | - |
| Enterprise Value (EV) 1 | 1,395 | 1,794 | 1,745 | 951.2 | 1,286 | 2,440 | 2,517 | 2,576 |
| Change | - | 28.64% | -2.73% | -45.5% | 35.21% | 89.72% | 3.14% | 2.37% |
| P/E | -23.6x | -18.6x | -13.6x | -10.3x | -6.96x | -8.88x | -8.82x | -12.6x |
| PBR | - | - | - | 2.25x | 3.43x | 5.25x | 5.33x | 6.46x |
| PEG | - | -0.4x | -0.6x | 0.6x | -0.1x | -0.8x | -13.16x | 0.4x |
| Capitalization / Revenue | 388x | 891x | 315x | 239x | 1,168x | 1,148x | 253x | 18.2x |
| EV / Revenue | 300x | 761x | 254x | 136x | 832x | 926x | 210x | 15.5x |
| EV / EBITDA | - | - | -11.3x | -4.96x | -4.53x | -7.12x | -6.58x | -9.65x |
| EV / EBIT | -19.6x | -15.6x | -12.3x | -4.88x | -4.48x | -7.06x | -6.7x | -9.38x |
| EV / FCF | -22.4x | -17x | -16x | -5.96x | -6.02x | -8.69x | -8.97x | -13.2x |
| FCF Yield | -4.46% | -5.88% | -6.25% | -16.8% | -16.6% | -11.5% | -11.2% | -7.59% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.64 | -2.4 | -2.92 | -2.45 | -3.9 | -4.339 | -4.368 | -3.047 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 4.651 | 2.357 | 6.883 | 7.02 | 1.545 | 2.635 | 11.96 | 166.2 |
| EBITDA 1 | - | - | -154.5 | -191.9 | -284 | -342.6 | -382.3 | -266.9 |
| EBIT 1 | -71.24 | -115.2 | -142 | -195.1 | -287.4 | -345.7 | -375.7 | -274.6 |
| Net income 1 | -70.51 | -112.3 | -141.4 | -157.9 | -258.8 | -330.1 | -370.5 | -269.4 |
| Net Debt 1 | -408.2 | -305 | -423.6 | -725.3 | -518.6 | -584.1 | -507.4 | -447.8 |
| Reference price 2 | 38.64 | 44.57 | 39.66 | 25.27 | 27.16 | 38.53 | 38.53 | 38.53 |
| Nbr of stocks (in thousands) | 46,664 | 47,100 | 54,689 | 66,344 | 66,449 | 78,492 | - | - |
| Announcement Date | 2/28/22 | 2/28/23 | 2/26/24 | 2/27/25 | 2/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.88x | 926.16x | -7.12x | -.--% | 3.02B | |
| 35.54x | 6.21x | 19.2x | 0.93% | 50.61B | |
| -23.03x | 336.22x | -21.72x | -.--% | 39.11B | |
| 25.26x | 2.79x | 12.08x | -.--% | 34.64B | |
| 45.78x | 4.59x | 29.44x | -.--% | 33.79B | |
| 27.04x | 7.93x | 19.9x | 0.42% | 26.89B | |
| 31.27x | 5.04x | 22.95x | -.--% | 15.14B | |
| 24.14x | 2.05x | 9.02x | 1.11% | 13.85B | |
| 23.51x | 1.87x | 11.36x | -.--% | 12.72B | |
| Average | 20.07x | 143.65x | 10.57x | 0.27% | 25.53B | |
| Weighted average by Cap. | 22.31x | 73.37x | 11.60x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CLDX Stock
- Valuation Celldex Therapeutics, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
